Ravi Vij

1999–2026 年に発表

147
論文数
21,104
被引用数
75
h 指数
143
i10 指数

被引用数

Ravi Vij の年別被引用数1999 年: 被引用 1 件2000 年: 被引用 4 件2001 年: 被引用 3 件2002 年: 被引用 7 件2003 年: 被引用 5 件2004 年: 被引用 5 件2005 年: 被引用 4 件2006 年: 被引用 2 件2007 年: 被引用 6 件2008 年: 被引用 6 件2009 年: 被引用 25 件2010 年: 被引用 41 件2011 年: 被引用 87 件2012 年: 被引用 128 件2013 年: 被引用 206 件2014 年: 被引用 242 件2015 年: 被引用 219 件2016 年: 被引用 223 件2017 年: 被引用 249 件2018 年: 被引用 233 件2019 年: 被引用 781 件2020 年: 被引用 899 件2021 年: 被引用 964 件2022 年: 被引用 761 件2023 年: 被引用 599 件2024 年: 被引用 1,038 件2025 年: 被引用 441 件2026 年: 被引用 19 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,003 件、この内訳の 28.6%中国: 引用元論文 764 件、この内訳の 7.3%ドイツ: 引用元論文 669 件、この内訳の 6.4%イタリア: 引用元論文 645 件、この内訳の 6.1%イギリス: 引用元論文 549 件、この内訳の 5.2%フランス: 引用元論文 521 件、この内訳の 4.9%スペイン: 引用元論文 474 件、この内訳の 4.5%カナダ: 引用元論文 384 件、この内訳の 3.6%オランダ: 引用元論文 335 件、この内訳の 3.2%オーストラリア: 引用元論文 230 件、この内訳の 2.2%日本: 引用元論文 219 件、この内訳の 2.1%ベルギー: 引用元論文 189 件、この内訳の 1.8%
0%28.6%その他 24.1%

分野

  • Medicine73.2%
  • Biochemistry, Genetics and Molecular Biology19.3%
  • Immunology and Microbiology5.4%
  • Engineering0.6%
  • Computer Science0.3%
  • Mathematics0.3%
  • その他0.9%

トピック

  • Multiple Myeloma Research and Treatments12.6%
  • Protein Degradation and Inhibitors6.5%
  • Acute Myeloid Leukemia Research5.3%
  • Hematopoietic Stem Cell Transplantation4.7%
  • CAR-T cell therapy research4.5%
  • Cancer Genomics and Diagnostics3.1%
  • その他63.3%

共著者

全論文

検索で開く
  1. Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2023 被引用: 705

  2. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Leukemia 2019 被引用: 616

  3. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Pieter Sonneveld, Hermann Einsele, Philippe Moreau - Leukemia 2022 被引用: 240

  4. Epigenetic regulation during cancer transitions across 11 tumour types

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Russell K. Pachynski, Julie K. Schwarz, William E. Gillanders, Albert H. Kim, Ravi Vij, John F. DiPersio, Sidharth V. Puram, Milan G. Chheda, Katherine C. Fuh, David G. DeNardo, Ryan C. Fields, Feng Chen, Benjamin J. Raphael, Li Ding - Nature 2023 被引用: 200

  5. Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Raymond L. Comenzo, Monika Engelhardt, Thomas Illmer, Philip Vlummens, Chantal Doyen, Thierry Façon, Lionel Karlin, Aurore Perrot, Klaus Podar, Michael Kauffman, Sharon Shacham, Lingling Li, Shijie Tang, Carla Picklesimer, Jean‐Richard Saint‐Martin, Marsha Crochiere, Hua Chang, Samir Parekh, Yosef Landesman, Jatin J. Shah, Paul G. Richardson, Sundar Jagannath - New England Journal of Medicine 2019 被引用: 673

  6. Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , S. Vincent Rajkumar, Shaji Kumar, Rafaël Fonseca, Greg Ahmann, P. Leif Bergsagel, A. Keith Stewart, Craig C. Hofmeister, Yvonne A. Efebera, Sundar Jagannath, Ajai Chari, Suzanne Trudel, Donna Reece, Jeffrey Wolf, Thomas Martin, Todd M. Zimmerman, Cara A. Rosenbaum, Andrzej Jakubowiak, Daniel Lebovic, Ravi Vij, Keith Stockerl-Goldstein - Cancer Cell 2014 被引用: 1,004

  7. A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation Antigen × CD3 Bispecific T-Cell Redirecting Antibody, in Patients With Relapsed/Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2022 被引用: 123

  8. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Madina Sukhanova, Randall W. Knoebel, Wendy Stock, Timothy A. Graubert, Matthew J. Walter, Peter Westervelt, Daniel C. Link, John F. DiPersio, Timothy J. Ley - New England Journal of Medicine 2016 被引用: 784

  9. CD56bright NK cells exhibit potent antitumor responses following IL-15 priming

    著者: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2017 被引用: 311

  10. Initial genome sequencing and analysis of multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Robb Onofrio, Trevor J. Pugh, S. Vincent Rajkumar, Alex H. Ramos, David S. Siegel, Andrey Sivachenko, A. Keith Stewart, Suzanne Trudel, Ravi Vij, Douglas Voet, Wendy Winckler, Todd M. Zimmerman, John D. Carpten, J.M. Trent, William C. Hahn, Levi A. Garraway, Matthew Meyerson, Eric S. Lander, Gad Getz, Todd R. Golub - Nature 2011 被引用: 1,455

  11. Efficacy of venetoclax as targeted therapy for relapsed/refractory t(11;14) multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , - Blood 2017 被引用: 527

  12. SciClone: Inferring Clonal Architecture and Tracking the Spatial and Temporal Patterns of Tumor Evolution

    著者: , , , , , , , , , , , , , , , , - PLoS Computational Biology, PLoS Comput. Biol. 2014 被引用: 495

  13. Co-evolution of tumor and immune cells during progression of multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2021 被引用: 136

  14. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2015 被引用: 654

  15. Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Sunita Nathan, Aziz Nazha, Taiga Nishihori, Sagar S. Patel, Attaphol Pawarode, David A. Rizzieri, Bipin N. Savani, Sachiko Seo, Melhem Solh, Celalettin Üstün, Marjolein van der Poel, Leo F. Verdonck, Ravi Vij, Baldeep Wirk, Betül Oran, Ryotaro Nakamura, Bart L. Scott, Wael Saber - JAMA Oncology 2022 被引用: 78

  16. Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael E. Kelly, Michele Seiler, Cara A. Rosenbaum, Parameswaran Hari, Marcelo C. Pasquini, Mary M. Horowitz, Thomas C. Shea, Steven M. Devine, Kenneth C. Anderson, Charles Linker - New England Journal of Medicine 2012 被引用: 1,143

  17. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ashraf Badros, Philippe Moreau, K Kim, P R Otero, J H Lee, Chaim Shustik, Daniel D. Waller, Wee Joo Chng, Shuji Ozaki, J-J Lee, Javier de la Rubia, Hyeon‐Seok Eom, Laura Rosiñol, Juan José Lahuerta, Anna Sureda, Jin Seok Kim, B G M Durie - Leukemia 2017 被引用: 354

  18. Cellular stressors contribute to the expansion of hematopoietic clones of varying leukemic potential

    著者: , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2018 被引用: 198

  19. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew A. Lunning, Michael P. Chu, Carter Milner, Allyson Harroff, Mark E. Graham, Spencer H. Shao, Jyothi Dodlapati, Carlos Fernández de Larrea, Leonard Klein, Charles Kuzma, Rafaël Fonseca, Gemma Azaceta, Miquel Granell, Carmen Martínez‐Chamorro, Rama Balaraman, Carlos Fernandes da Silva, Anabelle Chinea, Caitlin Costello, Suman Kambhampati, DeQuincy Andrew Lewis, Michael L. Grossbard, Kathleen J. Yost, Robert Robles, Michaël Sébag, Wayne Harris, Justinian R. Ngaiza, Michael Bär, Marie Shieh, Fredrick Min, Adedayo A. Onitilo, Fabio Volterra, William Wachsman, Madhuri Yalamachili, Eugènia Abella, Larry J. Anderson, Joan Bargay, Hani Hassoun, Gerald C Hsu, Hakan Kaya, Alex R. Menter, Dilip Patel, Donald Richards, William B. Solomon, Robert F. Anderson, Sumeet Chandra, Miguel Á. Conde, Saulias Girnius, May Matkiwsky, Isabel Krsnik, Shaji Kumar, Albert Oriol, Paula Rodríguez, Vivek Roy, Shanti Srinivas, Ronald G. Steis, Austin Christofferson, Sara Nasser, Jessica L. Aldrich, Christophe Legendre, Brooks A. Benard, C. S. Miller, Bryce Turner, Ahmet Kurdoglu, Megan Washington, Venkata D. Yellapantula, Jonathan Adkins, Lori Cuyugan, Martin Boateng, Adrienne Helland, Shari Kyman ほか 29 名 - Nature Genetics 2024 被引用: 75

  20. Nanoparticle T-cell engagers as a modular platform for cancer immunotherapy

    著者: , , , , , , , , , , , - Leukemia 2021 被引用: 63

  21. Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ravi Vij, John F. DiPersio - Nature Medicine 2023 被引用: 73

  22. Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma

    著者: , , , , , , , , , , , , , , , , , , , , - Blood 2023 被引用: 26

  23. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Saad Z. Usmani, Ravi Vij, Jeffrey L. Wolf, Jeffrey A. Zonder, P. Leif Bergsagel, Daniel Auclair, Hearn Jay Cho, Dan R. Robinson, Arul M. Chinnaiyan - Nature Communications 2022 被引用: 91

  24. Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Nature Communications 2020 被引用: 75